Edward P. Feener - 07 Jan 2022 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Scientific Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
07 Jan 2022
Net transactions value
+$434,832
Form type
4
Filing time
11 Jan 2022, 15:42:57 UTC
Previous filing
03 Nov 2021
Next filing
19 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise $238,966 +33,800 +1513% $7.07 36,034 07 Jan 2022 Direct
transaction KALV Common Stock Options Exercise $195,866 +23,857 +66% $8.21 59,891 07 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Employee Stock Option (right to buy) Options Exercise $0 -33,800 -100% $0.000000* 0 07 Jan 2022 Common Stock 33,800 $7.07 Direct F1
transaction KALV Employee Stock Option (right to buy) Options Exercise $0 -23,857 -46% $0.000000 27,943 07 Jan 2022 Common Stock 23,857 $8.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested.
F2 The option vests over a 4 year period: 1/48th on July 4, 2018, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.